CROI 2015 David Wyles presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.comTreatment outcomesHCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy Cindy Zahnd presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.comHepatitis C treatmentDeferring hepatitis C treatment can lead to liver cancer and death, despite cure. David Wyles and Susanna Naggie presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.comHIV/HCV co-infectionTwo interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection infohep news Treatment outcomes HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy Liz Highleyman / 23 April 2015 Direct-acting antiviral regimens containing sofosbuvir (Sovaldi) and the drugs in Viekirax/Exviera were highly effective regardless of how soon hepatitis C viral load became undetectable after starting treatment, according to research presented at the recent ... Transmission and prevention Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR Michael Carter / 18 March 2015 Rates of hepatitis C virus (HCV) reoccurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI ... Treatment outcomes Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir Liz Highleyman / 18 March 2015 Almost all patients with hepatitis C virus alone or HIV/HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA ... Prognosis and disease progression Progression to severe fibrosis or cirrhosis is common among baby boomers with hepatitis C in the US Liz Highleyman / 05 March 2015 The burden of hepatitis C virus (HCV) infection is high in the US, with a substantial number of individuals born between 1945 and 1965 having advanced fibrosis or cirrhosis and therefore being at ... Deciding when and how to treat HCV Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... Treatment for people living with HIV and HCV Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection Liz Highleyman / 04 March 2015 A pair of two-drug, 12-week regimens containing neither interferon nor ribavirin – sofosbuvir (Sovaldi) plus either ledipasvir (the Harvoni coformulation) or daclatasvir (Daklinza) – cured hepatitis C for more than 95% of ... View more > Editors' picks from other sources Treatment in liver transplanted HIV did not affect HCC recurrence or survival after liver transplant Healio Hepatology / 04 March 2015 Finance, funding & health economics HCV Drugs Costly but Cure Might Not Be MedPage Today Gastroenterology / 04 March 2015 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive